recombinant mutated vimentin

Recombinant mutated vimentin is a preclinical-stage recombinant protein asset developed by the Republican Research and Practical Center of Transfusion and Medical Biotechnologies in Belarus. Vimentin is a type III intermediate filament protein that plays a crucial role in maintaining cellular integrity and is involved in various signaling pathways. Mutated or post-translationally modified forms of vimentin, such as mutated citrullinated vimentin (MCV), are well-characterized antigens in the context of autoimmune diseases, particularly rheumatoid arthritis, where they trigger the production of highly specific autoantibodies. This asset is intended for research and the development of immunologic interventions, potentially acting as a targeted immunomodulator or as a component in diagnostic and therapeutic platforms for autoimmune conditions.

Other names

mutated vimentin